Clinical pharmacokinetics and use of infliximab
U Klotz, A Teml, M Schwab - Clinical pharmacokinetics, 2007 - Springer
Tumor necrosis factor-α (TNFα) is a key proinflammatory cytokine involved in chronic
inflammatory diseases. Infliximab, a chimeric (human-murine) monoclonal IgG1 anti-TNFα …
inflammatory diseases. Infliximab, a chimeric (human-murine) monoclonal IgG1 anti-TNFα …
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target …
Background Current recommendations for the management of axial spondyloarthritis (SpA)
and psoriatic arthritis are to monitor disease activity and adjust therapy accordingly …
and psoriatic arthritis are to monitor disease activity and adjust therapy accordingly …
Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease
D Sorrentino, A Paviotti, G Terrosu, C Avellini… - Clinical …, 2010 - Elsevier
BACKGROUND & AIMS: Infliximab might prevent postsurgical recurrence of Crohn's
disease. However, it is unclear whether long-term therapy with this drug is necessary and …
disease. However, it is unclear whether long-term therapy with this drug is necessary and …
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatment
M Breban, P Ravaud, P Claudepierre… - Arthritis & …, 2008 - Wiley Online Library
Objective Continuous treatment with the anti–tumor necrosis factor α (anti‐TNFα) antibody
infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation …
infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation …
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
F Cantini, L Niccoli, E Cassarà, O Kaloudi… - Biologics: Targets and …, 2013 - Taylor & Francis
Background The aim of this study was to evaluate the proportion of patients with ankylosing
spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept …
spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept …
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
DM van der Heijde, DA Revicki, KL Gooch… - Arthritis research & …, 2009 - Springer
Introduction We evaluated the three-year impact of adalimumab on patient-reported physical
function and health-related quality-of-life (HRQOL) outcomes in patients with active …
function and health-related quality-of-life (HRQOL) outcomes in patients with active …
Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial
M Yates, LE Hamilton, F Elender, L Dean… - The Journal of …, 2015 - jrheum.org
Objective. To investigate, in a pilot randomized controlled trial, whether etanercept (ETN) 25
mg once weekly is effective at maintaining a clinical response in patients with ankylosing …
mg once weekly is effective at maintaining a clinical response in patients with ankylosing …
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis
RD Inman, WP Maksymowych - The Journal of rheumatology, 2010 - jrheum.org
Objective. The tumor necrosis factor-α (TNF-α) inhibitor infliximab (IFX) has been proven
effective for the treatment of ankylosing spondylitis (AS). The primary objective of this double …
effective for the treatment of ankylosing spondylitis (AS). The primary objective of this double …
Tapering of TNF inhibitors in axial spondyloarthritis in routine care—2-year clinical and MRI outcomes and predictors of successful tapering
M Wetterslev, S Georgiadis, IJ Sørensen… - …, 2022 - academic.oup.com
Objectives In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in
clinical remission who tapered TNF inhibitor (TNFi) treatment according to a clinical …
clinical remission who tapered TNF inhibitor (TNFi) treatment according to a clinical …
Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease
V Navarro-Compán, V Moreira, R Ariza-Ariza… - Clinical …, 2011 - Springer
This study aims to explore the effectiveness of low dose of etanercept (ETN) in patients with
ankylosing spondylitis (AS) who achieve a good control of their disease in daily clinical …
ankylosing spondylitis (AS) who achieve a good control of their disease in daily clinical …